Using genetic predictors of CA125 to improve personalized ovarian cancer screening Most ovarian cancer cases are currently diagnosed at late stage when less than half of the women will live five years after their diagnosis. In contrast, ovarian cancer cases diagnosed at an early stage have more than 90% living after five years from diagnosis. […]
Read More
Elizabeth Poole, PhDBrigham and Women’s Hospital2015 Skacel Family Scholar Medication use and ovarian cancer survival Although factors that contribute to ovarian cancer risk prior to diagnosis are currently being teased apart, factors which contribute to survival after a diagnosis of ovarian cancer have not yet been well studied. Dr. Poole’s project will develop the Nurses’ […]
Read More
Daniela Dinulescu, PhDEugene Braunwald Research Center, Harvard Medical Center Targeted therapeutic strategies and early detection biomarkers in ovarian cancer Epithelial ovarian cancer is the leading cause of death among gynecological cancers. We will actively discover, identify and validate disease biomarkers associated with early disease. The data collected from these key preclinical studies will be instrumental […]
Read More
Shu-Wing Ng, PhD, BScHarvard / Brigham and Women’s Hospital Characterization of lipid metabolic enzymes in ovarian cancer This study will confirm the expression and activity of two important enzymes and investigate the effects of inhibiting these enzymes. The results will provide information regarding their role in ovarian cancer and have an impact on screening, surveillance […]
Read More
Daniela Dinulescu, PhDBrigham and Women’s Hospital Nanotechology-based Therapy Targeting Platinum Resistant Disease An exciting new hypothesis in ovarian cancer biology is that tumor development is driven by cancer stem cells, which are resistant to standard chemotherapies and consequently responsible for the high rate of tumor relapse seen in patients. Animal models, which accurately recapitulate the […]
Read More
Daniela Dinulescu, PhDBrigham and Women’s Hospital Experimental Models to Validate a Tubal Cell of Origin for Serous Ovarian Cancer Too little is known about the genetic lesions responsible for ovarian cancer tumor initiation, and uncertainty remains over the specific cell or cells of origin. Data emerging from The Cancer Genome Atlas (TCGA) on the many […]
Read More